Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma, Non-Hodgkin 2Rhabdoid Tumor 1Recurrence 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Glioma 1Ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Choroid Plexus Carcinoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Vincristine 2Radiotherapy 2Cyclophosphamide 2Cisplatin 2Pemetrexed 1Maintenance Chemotherapy 1Lomustine 1Induction Chemotherapy 1HhAntag691 1Gemcitabine 1Exercise 1Diploidy 1Craniospinal Irradiation 1Carboplatin 1CLR1404 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroectodermal Tumors, Primitive × Automobiles × Clear all
NCT03500991 2025-12-17

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Seattle Children's Hospital

Phase 1 Active not recruiting
10 enrolled
CNS

Choroid Plexus Carcinoma, Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Neoplasms, Germ Cell and Embryonal, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡